First Author & Year of Publication | Country | Study design | ICO | S/M | level of evidencea | VEGF Inhibitors | Laser | MFT(m) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SS | Rec | Ret | Com | SE(D) | TTR(w) | SS | Rec | Ret | Com | SE(D) | TTR(w) | |||||||
Mintz-Hittner 2011 [13] | USA | RCT | YES | M | 2b | 140 | 6/4.3 | NG | 2/1.4 | NG | NG | 146 | 32/21.9 | NG | 6/4.1 | NG | NG | 8 |
Harder 2013 [16] | Germany | CNS | YES | S | 3 | 23 | 0/0 | 0/0 | 0/0 | −1.04 ± 4.24 | NG | 26 | 1/3.8 | 1/3.8 | 1/3.8 | −4.41 ± 5.50 | NG | 12 |
Moran 2014 [12] | Ireland | RCT | YES | S | 2b | 14 | 3/21.4 | 3/21.4 | NG | NG | 16.00 ± 1.00 | 14 | 1/7.1 | 1/7.1 | NG | NG | 2.00 ± 0.01 | 24 |
Lepore 2014 [24] | Italy | RCT | YES | S | 2b | 12 | 0/0 | 0/0 | 0/0 | NG | NG | 12 | 1/8.3 | 1/8.3 | 1/8.3 | NG | NG | 9 |
Isaac 2015 [8] | Canada | CNS | YES | S | 3 | 23 | 0/0 | 0/0 | 0/0 | −3.57 ± 6.19 | NG | 22 | 1/4.5 | 1/4.5 | 0/0 | −6.39 ± 4.41 | NG | >9 |
Hwang 2015 [9] | USA | CNS | YES | S | 3 | 22 | 3/13.6 | NG | 0/0 | 2.40 ± 3.50 | 9.00 ± 5.70 | 32 | 1/3.1 | NG | 6/18.8 | −5.30 ± 5.40 | 2.60 ± 0.01 | 6–40 |
Gunay 2016 [11] | Turkey | CNS | YES | M | 3 | 133 | 28/21.1 | 12/9.0 | NG | NG | NG | 111 | 1/0.9 | 0/0 | NG | NG | NG | 18 |
Karkhaneh 2016 [25] | Iran | RCT | YES | S | 2b | 86 | 9/10.5 | 9/10.5 | 0/0 | NG | 5.07 ± 1.66 | 72 | 1/1.4 | 1/1.4 | 0/0 | NG | 3 ± 0.01 | 22.5 |
Mueller 2016 [7] | Germany | CNS | YES | S | 3 | 74 | 7/9.5 | 5/6.8 | 1/1.4 | NG | NG | 34 | 0/0 | 0/0 | 4/11.8 | NG | NG | 12 |
Walz 2016 [26] | Germany | CNS | YES | M | 3 | 33 | NG | 5/15.1 | NG | NG | NG | 129 | NG | 18/14.0 | NG | NG | NG | – |
 |  |  |  |  |  | 560 |  |  |  |  |  | 598 |  |  |  |  |  |  |